Press Releases

Press Releases

July 19, 2018
WOBURN, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Replimune Group, Inc., a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the pricing of its initial public offering of 6,700,000 shares of common stock at a public offering price of
June 22, 2018
Woburn, MA, June 22, 2018  – Replimune Group Inc., a biotechnology company developing next generation oncolytic immunotherapies, announced today it has appointed Dieter K. Weinand to its Board as an independent non-executive Director. “We are pleased to welcome Dieter to Replimune’s Board as we
June 11, 2018
Woburn, MA, June 11, 2018  – Replimune Group Inc., a biotechnology company developing next generation oncolytic immunotherapies, announced today it has appointed Hyam I. Levitsky, M.D. to the company’s Board as an independent non-executive Director. “Hy is a leading expert in immuno-oncology with